Golimumab biosimilar - Reliance Life Sciences
Alternative Names: R-TPR-044Latest Information Update: 17 Nov 2021
At a glance
- Originator Reliance Life Sciences
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 28 Nov 2020 Reliance Life Sciences plans a phase III trial for Rheumatoid Arthritis (Adjuvant therapy, Treatment experienced) in India (SC) (CTRI/2020/09/027958)
- 04 Nov 2020 Preclinical trials in Rheumatoid arthritis in India (SC) prior to November 2020